Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.

Autor: Amaro, Adriana1 (AUTHOR), Reggiani, Francesco1 (AUTHOR), Fenoglio, Daniela1,2 (AUTHOR), Gangemi, Rosaria1 (AUTHOR), Tosi, Anna3 (AUTHOR), Parodi, Alessia1 (AUTHOR), Banelli, Barbara1 (AUTHOR), Rigo, Valentina1 (AUTHOR), Mastracci, Luca1 (AUTHOR), Grillo, Federica1 (AUTHOR), Cereghetti, Alessandra4 (AUTHOR), Tastanova, Aizhan4 (AUTHOR), Ghosh, Adhideb5 (AUTHOR), Sallustio, Fabio6 (AUTHOR), Emionite, Laura1 (AUTHOR), Daga, Antonio1 (AUTHOR), Altosole, Tiziana1 (AUTHOR), Filaci, Gilberto1,2 (AUTHOR), Rosato, Antonio3,7 (AUTHOR), Levesque, Mitchell4 (AUTHOR)
Zdroj: Journal of Experimental & Clinical Cancer Research (17569966). 3/18/2023, Vol. 42 Issue 1, p1-24. 24p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje